US agency committee rejects booster dose of Pfizer vaccine against Kovid coronavirus

US agency committee rejects booster dose of Pfizer vaccine against Kovid  coronavirus

Voting took place this Friday (17): 16 votes in opposition and 2 votes in favor. The decision was a setback for the government’s efforts Joe Biden In strengthening people’s defenses against the virus and its most contagious new variant, the delta variant.

The discussions of the committee lasted for several hours and independent experts The FDA argued that Pfizer presented too little data On the safety of applying extra doses. In addition, he complained that the data provided by Israeli researchers about his booster campaign may not be sufficient to predict the American experience.

In recent days, scientists inside and outside the US government have been divided over the need to administer a booster dose of the COVID vaccine. World Health Organization (WHO) opposes the measure: the health wing of the United Nations advocates that doses be distributed first to the poorest countries.

The FDA committee took into account the studies presented so far on the subject. Although evidence suggests that the immunity level of the two-dose vaccine drops after a few months, the vaccine remains effective against severe cases and deaths due to the coronavirus – even taking the delta version into account. .

See also  Australia adopts new restrictions after increase in cases

About the author: Muhammad Wayne

Wayne is a reporter who covers everything from oil trading to China's biggest conglomerates and technology companies. Originally from Chicago, he is a graduate of New York University's business and economic reporting program.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *